Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kellie Bruening"'
Autor:
Ronald Sobecks, Jerome B. Zeldis, Matt Kalaycio, Janice Reed, Aleksandr Lazaryan, Steven Andresen, Rachid Baz, Kimberly Hamilton, Beth Faiman, Mary Ann Karam, Joel Waksman, Gordan Srkalovic, Frederic J. Reu, John Sweetenham, Robert M. Dean, Robert Knight, Becky Habecker, Kellie Bruening, Mohamad A. Hussein
Publikováno v:
American Journal of Hematology. 89:349-354
A previous interim report of MM-011, the first study that combined lenalidomide with anthracycline-based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multiple myeloma (RRMM), showed promising safety and activity. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::048b564f3a31c242a0e09aef96b6f0b5
https://doi.org/10.1002/ajh.23639
https://doi.org/10.1002/ajh.23639
Autor:
Aleksandr, Lazaryan, Mohamad A, Hussein, Frederic J, Reu, Beth, Faiman, Becky, Habecker, Mary, Ann Karam, Janice, Reed, Kimberly, Hamilton, Joel, Waksman, Kellie, Bruening, Gordan, Srkalovic, Steven, Andresen, Matthew, Kalaycio, John W, Sweetenham, Ronald, Sobecks, Robert, Dean, Robert, Knight, Jerome B, Zeldis, Rachid, Baz
Publikováno v:
American journal of hematology. 89(4)
A previous interim report of MM-011, the first study that combined lenalidomide with anthracycline-based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multiple myeloma (RRMM), showed promising safety and activity. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d1875932469c73dc426996e732f90812
https://pubmed.ncbi.nlm.nih.gov/24273135
https://pubmed.ncbi.nlm.nih.gov/24273135
Autor:
M. A. Karam, J. Zeldis, Mohamad A. Hussein, G Srkalovic, Y Ellis, Robert Knight, Rony Abou Jawde, Janice Reed, Toni K. Choueiri, Esteban Walker, Kellie Bruening, Steven Andresen, Catherine Brand, Beth Faiman, Rachid Baz
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 17(12)
Background Lenalidomide is active and well tolerated in relapsed and refractory multiple myeloma. We conducted a phase I/II trial of the combination of lenalidomide and chemotherapy to evaluate the safety and efficacy of the combination. Methods The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::715aadb4a82a01c03b7d74c85d5f73f5
https://pubmed.ncbi.nlm.nih.gov/16980599
https://pubmed.ncbi.nlm.nih.gov/16980599
Autor:
Mitchell R. Smith, Christy J. Samaras, Robert M. Dean, Debbie Hastings, Frederic J. Reu, Jason Valent, Hien K. Duong, Paul Elson, Surbhi Sidana, Kellie Bruening, Beth Faiman
Publikováno v:
Blood. 122:1975-1975
Background Information is limited on the efficacy and long-term tolerability of weekly ubcutaneous (SC) bortezomib (BTZ), especially when given alone or combined only with glucocorticoids. We implemented use of SC BTZ in 12/2010 and based on equal AU
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c25819a0d0873899de13f4907214055
https://doi.org/10.1182/blood.v122.21.1975.1975
https://doi.org/10.1182/blood.v122.21.1975.1975
Autor:
Beth Faiman, Robert M. Dean, Hien K. Duong, Mitchell R. Smith, Paul Elson, Debbie Hastings, Kellie Bruening, Christy J. Samaras, Frederic J. Reu, Jason Valent, Surbhi Sidana
Publikováno v:
Blood. 122:5397-5397
Background We hypothesized lenalidomide (len) related diarrhea (LRD) may correlate with activation of an immune response against multiple myeloma (MM) based on colon biopsies that showed crypt apoptosis reminiscent of GVHD in 3 MM patients with sever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d98840035cb3d508304a1058362aebec
https://doi.org/10.1182/blood.v122.21.5397.5397
https://doi.org/10.1182/blood.v122.21.5397.5397
Autor:
Kimberly Hamilton, Jerome B. Zeldis, Rachid Baz, Gordan Srkalovic, Mohamad A. Hussein, Ronald Sobecks, Aleksandr Lazaryan, Becky Habecker, Robert M. Dean, Mary Ann Karam, Robert Knight, Steven Andresen, John Sweetenham, Frederic J. Reu, Janice Reed, Matt Kalaycio, Paul Elson, Beth Faiman, Kellie Bruening
Publikováno v:
Blood. 116:1967-1967
Abstract 1967 Background: An initial report of MM011 described the MTD and promising activity in the first 62 patients (pts) (Baz R et al, Ann Oncol 2006). Here we report complete outcomes of the entire study cohort (n=77) with over four years since
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e54063fc988e1e7c4f10d58813e7ecda
https://doi.org/10.1182/blood.v116.21.1967.1967
https://doi.org/10.1182/blood.v116.21.1967.1967
Autor:
Kathe Balinski, Janice Reed, Greg L. Pearce, Mohamad A. Hussein, Kellie Bruening, Marta Olesnyckyj, Paul Sartori, Jerome B. Zeldis, Mary Ann Karam, Robert Knight, Catherine Brand, Gordan Srkalovic
Publikováno v:
Blood. 104:208-208
DVd in combination with Thalidomide (T) and the appropriate supportive care measures resulted in a high response rate (88%) as well as an improved quality response (50% CR & NCR) similar to what is achieved with high dose therapy. Immunomodulatory dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8ba27a3988d26109b67daded8b8707c
https://doi.org/10.1182/blood.v104.11.208.208
https://doi.org/10.1182/blood.v104.11.208.208